The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?
Background: MS is a highly heterogeneous disease, both in its course and in its response to treatments. Effective biomarkers may help predict disability progression and monitor patients’ treatment responses. <br/>Objective: To focus on how biomarkers may contribute to treatment individualisat...
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
SAGE Publications
2016
|